Overview

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

Eligibility

Inclusion Criteria:

• Aged ≥18 years at index date.
• Have a confirmed diagnosis of schizophrenia before index date.
• Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy.
• Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines.
• Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish).
• English or Spanish speaking.

Exclusion Criteria:

• Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening.
• Evidence of use of XT prior to time of eligibility screening.